---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-116331"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-04-25T23:59:59+00:00"
generated_at: "2026-06-26T05:13:00.993911+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead forms JV with Vivo Capital for Greater China; licenses four RNAi cardiometabolic drugs

## Summary
- Vivo Capital provided $60M initial funding to Visirna Therapeutics, JV in which Arrowhead holds majority stake.
- Visirna gets exclusive rights to develop and commercialize four investigational RNAi therapeutics in Greater China.
- Arrowhead eligible to receive royalties on net commercial sales in the licensed territory.
- Vivo Capital's Hongbo Lu and Gaurav Aggarwal to join Visirna board; Arrowhead also appoints board members.
- Visirna to be headquartered in Shanghai; recruitment of management and staff underway.

## SEC filing metadata
- accession: 0001193125-22-116331
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000119312522116331/0001193125-22-116331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000119312522116331/d203945d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-116331
- JSON: https://secwatch.observer/filing/0001193125-22-116331.json
- Plain text: https://secwatch.observer/filing/0001193125-22-116331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.